GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New shot vs IV: could a simpler injection improve stomach cancer treatment?
Disease control Not yet recruitingThis phase 3 study tests whether a shot (subcutaneous) form of the drug AK104 works as well as the IV form when combined with chemotherapy for advanced stomach or gastroesophageal junction cancer. About 422 people who have not had prior treatment for their advanced cancer will ta…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
New hope for advanced gut cancers? drug combo trial launches
Disease control Not yet recruitingThis study tests a new drug called SSGJ-706 combined with standard treatments for people with advanced cancers of the stomach, colon, pancreas, or esophagus that cannot be removed by surgery. About 300 adults aged 18-75 will take part to see if the combination is safe and helps s…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug duo aims to shrink stomach tumors before surgery
Disease control Not yet recruitingThis study tests whether adding the targeted drug zanidatamab to standard chemotherapy before surgery can shrink tumors more effectively in people with HER2-positive stomach or gastroesophageal junction cancer. About 30 adults with stage II/III cancer will receive the combination…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
Engineered immune cells take on advanced stomach cancer in new trial
Disease control Not yet recruitingThis early-stage trial is testing a new treatment called CT0494BCP for people with advanced stomach or gastroesophageal junction cancer who have already tried other treatments. The therapy uses specially engineered immune cells (CAR-T cells) to attack the cancer. The study will e…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New study aims to find best follow-up care for stomach cancer patients after successful initial treatment
Disease control Not yet recruitingThis study looks at 500 people with a type of stomach cancer who had surgery after chemotherapy and immunotherapy, and whose cancer was completely gone after surgery. Researchers want to see which follow-up treatment plan works best to keep the cancer from coming back. Participan…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Liaoning Cancer Hospital & Institute • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New hope for Hard-to-Treat cancers: targeted combo therapy enters Mid-Stage trial
Disease control Not yet recruitingThis study tests a new drug called IBI343 combined with other treatments for people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific marker (CLDN18.2). The goal is to see if the combination is safe and shrinks tumors. About 389 adults w…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
Stomach cancer mystery: why do some patients resist immunotherapy?
Knowledge-focused Not yet recruitingThis study looks at a specific type of stomach cancer (dMMR/MSI-H) that often responds well to immunotherapy, but about half of patients do not. Researchers want to understand why some patients benefit and others don't, by studying tumor samples before and during treatment. The g…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 04:20 UTC
-
Blood test may spare stomach cancer patients from unnecessary chemo
Knowledge-focused Not yet recruitingThis study aims to see if a blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide which stomach cancer patients need extra chemotherapy after surgery and which can safely skip it. About 304 people with locally advanced stomach cancer will be randomly assi…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 03:58 UTC
-
Blood test may spare stomach cancer patients from unnecessary chemo
Knowledge-focused Not yet recruitingThis study looks at whether a simple blood test that detects tiny traces of cancer DNA (called ctDNA) can help doctors decide which patients with advanced stomach cancer can safely skip chemotherapy after surgery. About 90 adults with stage III or IV stomach cancer will be enroll…
Matched conditions: GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated May 19, 2026 11:47 UTC